research on retatrutide Retatrutide, an experimental weight-loss drug, has not been approved by the FDA. But, doctors and nurse practitioners in clinics across the country are prescribing it anyway, a CBS News investigation Retatrutide 25mg – Research Peptide

Patients lose 15-25% of their body weight

Medication Options From what I can tell (and what was offered to me after my initial consultation), Medvi offers compounded semaglutide for $299/month or compounded tirzepatide for $499/month

J Neurosci (2015) 35(45):1496682

Purpose ELIXA was conducted to assess the cardiovascular safety of once-daily subcutaneously injected lixisenatide 20 mcg (Adlyxin) by documenting non-inferiority, as well as superiority, for the primary composite outcome of non-fatal myocardial infarction, non-fatal stroke, CV death, or hospitalization for unstable angina (4-point MACE) in an adult population with T2DM and extremely high CV risk